Vision, Study | search
Click here to view Vision, Study news from 60+ newspapers.
Bookmark or Share- Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate ...Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. Lutetium-177 (177 Lu)–PSMA-617 is a radioligand therapy that delivers beta-particle...
- Renal and Multiorgan Safety of - Journal of Nuclear MedicineThe VISION study included a dosimetry substudy that aimed to enhance the assessment of the safety profile of 177 Lu-PSMA-617 and to contextualize exposure levels against historical EBRT limits in patients with mCRPC.
- VISION: An international, prospective, open-label, multicenter ...VISION (NCT03511664) is a phase 3 study designed to assess the efficacy of 177 Lu-PSMA-617 in patients with PSMA-positive mCRPC. Methods: Patients were randomized 2:1 to receive best standard of care with or without 177 Lu-PSMA-617.
- Rapid Readouts: Results from the Phase 3 VISION Study - OncLiveThe objective of this study is to report results from the phase 3 VISION study (NCT03511664) of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC).
- Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration ...This dosimetry sub-study aimed to quantify the absorbed dose of 177 Lu-PSMA-617 in organs at risk of radiotoxicity due to exposure levels or radiosensitivity. Methods: In a sub-study of VISION, dosimetry was performed in a separate cohort of 29 non-randomized participants at four German sites.
More
